Claims for Patent: 9,765,351

Summary for Patent: 9,765,351

Title:	Modified gene silencing
Abstract:	This invention relates to methods of controlling gene expression or gene suppression in eukaryotic cells. One aspect of this invention includes modifying the degree of silencing of a target gene by use of a modified suppression element. Another aspect includes providing a eukaryotic cell having a desired phenotype resulting from transcription in the eukaryotic cell of a modified suppression element. Also provided are transgenic eukaryotic cells, transgenic plant cells, plants, and seeds containing modified suppression elements, and useful derivatives of such transgenic plant cells, plants, or seeds, such as food or feed products.
Inventor(s):	Fillatti; Joanne (Davis, CA), Goley; Jean C. (Chesterfield, MO), Heck; Gregory R. (Crystal Lake Park, MO), Munyikwa; Tichafa R. I. (Ballwin, MO), Vaughn; Ty T. (Clayton, MO), Voelker; Toni (Davis, CA)
Assignee:	MONSANTO TECHNOLOGY LLC (St. Louis, MO)
Application Number:	14/322,393
Patent Claims:	1. A population of soybean seeds, each seed comprising a DNA fragment, which comprises a truncated fragment of a fatty acid desaturase 2 (FAD2) intron and transcribes to RNA for suppressing FAD2 by forming a double-stranded RNA, wherein said population comprises at least three different lengths of said truncated FAD2 intron fragments, which are from 19 base pairs of a contiguous FAD2 intron in length to 400 base pairs of a contiguous FAD2 intron in length, wherein the amount of FAD2 suppression in each seed depends on the length of said truncated FAD2 intron fragment in said seed, and decreases in truncated FAD2 intron fragment length decrease the suppression of FAD2 in a seed, and wherein said DNA fragment comprises at least one anti-sense segment that is anti-sense to at least one segment of a FAD2 intron, and at least one sense segment that is at least one segment of a FAD2 intron, and wherein said FAD2 suppression results in at least one of said soybean seeds comprising said DNA fragment exhibits an oleic acid content of about 40% to about 85% by weight of the total fatty acids and a saturated fatty acid content of less than 8% by weight of the total fatty acids. 2. A population of soybean seeds, each seed comprising a DNA fragment, which comprises a truncated fragment of a fatty acid desaturase 2 (FAD2) intron and transcribes to RNA for suppressing FAD2 by forming a double-stranded RNA, wherein said population comprises at least three different lengths of said truncated FAD2 intron fragments, which are from 19 base pairs of a contiguous FAD2 intron in length to 400 base pairs of a contiguous FAD2 intron in length, wherein the amount of FAD2 suppression in each seed depends on the length of said truncated FAD2 intron fragment in said seed, and decreases in truncated FAD2 intron fragment length decrease the suppression of FAD2 in a seed, and wherein said DNA fragment comprises at least one anti-sense segment that is anti-sense to at least one segment of a FAD2 intron, and at least one sense segment that is at least one segment of a FAD2 intron, and wherein said FAD2 suppression results in at least one of said soybean seeds exhibit an average oleic acid content of about 40% to about 85% by weight of the total fatty acids and an average saturated fatty acid content of less than 8% by weight of the total fatty acids. 3. The population of claim 1, wherein said DNA fragment comprises at least one anti-sense segment that is anti-sense to at least one segment of a FAD2 intron, and at least one sense segment that is at least one segment of a FAD2 intron. 4. The population of claim 1, wherein said DNA fragment in at least one seed comprises a truncation of said FAD2 intron corresponding to a deletion of nucleotides from the 5' end of the at least one sense segment and the complementary nucleotides of the anti-sense segment. 5. The population of claim 1, wherein said DNA fragment in at least one seed comprises a truncation of said FAD2 intron corresponding to a deletion of nucleotides from the 3' end of the at least one sense segment and the complementary nucleotides of the anti-sense segment. 6. The population of claim 2, wherein said DNA fragment comprises at least one anti-sense segment that is anti-sense to at least one segment of a FAD2 intron, and at least one sense segment that is at least one segment of a FAD2 intron. 7. The population of claim 2, wherein said DNA fragment in at least one seed comprises a truncation of said FAD2 intron corresponding to a deletion of nucleotides from the 5' end of the at least one sense segment and the complementary nucleotides of the anti-sense segment. 8. The population of claim 2, wherein said DNA fragment in at least one seed comprises a truncation of said FAD2 intron corresponding to a deletion of nucleotides from the 3' end of the at least one sense segment and the complementary nucleotides of the anti-sense segment.

Details for Patent 9,765,351

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2026-02-13
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2026-02-13
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2026-02-13